Migraine Trial, Recruiting NCT05769348 Sponsor: University of Michigan Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT05769348
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years old (male or female)
  • People whose migraines first started before the age of 50
  • People who currently have chronic migraine, meaning headaches on 15 or more days per month for more than six months, with at least 8 of those days having migraine features
  • People who currently have low-frequency episodic migraine, meaning headaches on fewer than 8 days per month
  • People who are willing to avoid starting new treatments or medications during the study period

Who may not be able to join:

  • People who have significant pain in parts of the body other than the head
  • People who have an active, untreated serious illness other than migraine, such as heart or lung conditions, cancer, uncontrolled hormonal conditions, severe allergies, or systemic conditions like rheumatoid arthritis, lupus, gout, or fibromyalgia
  • People with a history of, or current, psychotic disorder (such as bipolar disorder or schizophrenia), or severe depression based on a standard depression scoring test
  • People with a history of a neurological condition such as epilepsy, stroke, or nerve pain disorders
  • People whose headaches are linked to overuse of certain pain medications — for example, taking triptans, ergotamine, or combination pain relievers on 10 or more days per month, or simple pain relievers (such as paracetamol, aspirin, or anti-inflammatories) on 15 or more days per month, for more than 3 months
  • People who currently use, or have used in the last 3 months, opioid medications, dopaminergic drugs, or recreational substances
  • People who test positive for opioids or recreational drugs (such as cannabis) at the time of brain scan visits
  • People with a known allergy to the radioactive tracers used in the study or to chemically similar medications
  • People who are excluded following safety screening for MRI or PET scanning (as assessed by study staff)
  • People who are pregnant or breastfeeding (a negative pregnancy test is required before any PET scan procedures)
  • People who have previously used tDCS (a type of mild electrical brain stimulation) (confirm with trial site if unsure)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexandre DaSilva, DDS, DMedSc, University of Michigan

Phone: (734)763-8469

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 January 2023
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in moderate to severe headache days over 1 month follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov